Abiopharma

🔍 Bizily Scott (Executive)

Company: 4D Molecular Therapeutics, Inc. (FDMT)

Report Date: 2026-06-23

Detailed Transactions and Holdings:

• Acquired 9,810 shares of Common Stock at $4.14 per share (Direct)
  Date: 2026-06-23 | Code: M | equity_swap_involved: false | shares_owned_after: 18,427.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 9,810 shares of Common Stock at $12.0 per share (Direct)
  Date: 2026-06-23 | Code: S | equity_swap_involved: false | shares_owned_after: 8,617.00 | transaction_form_type: 4
• Sold 9,810 shares of Stock Option (Right to Buy) at $4.14 per share (Derivative)
  Date: 2026-06-23 | Code: M | Expires: 2035-03-05 | equity_swap_involved: false | shares_owned_after: 63,785.00 | transaction_form_type: 4 | Footnotes: F2

Footnotes:

• F1: Reflects 5,023 shares of the Issuer's common stock purchased under the Issuer's Employee Stock Purchase Plan in a transaction exempt under Rule 16b-3.
• F2: The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of March 6, 2025 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company.